肠道菌群
肠道微生物群
微生物群
生物
肠道细菌
葡萄糖稳态
肠-脑轴
疾病
益生元
2型糖尿病
胃肠道
失调
糖尿病
生物信息学
免疫学
2型糖尿病
代谢性疾病
代谢综合征
人体胃肠道
普雷沃菌属
拟杆菌
计算生物学
微生物学
丁酸盐
双歧杆菌
粪便细菌疗法
作者
Savanna N. Weninger,Andrew Manley,Frank A. Duca
标识
DOI:10.1146/annurev-physiol-051524-094728
摘要
The gut microbiota is a salient contributor to the development of type 2 diabetes mellitus (T2D) as a vast and complex metabolic cross talk that exists between the bacteria residing in the gastrointestinal tract and the host. This cross talk is largely influenced by external factors including diet, highlighting a potential avenue to effectively manipulate the gut microbiota to treat metabolic diseases such as diabetes. In this review, we discuss the influence of the gut microbiota on T2D development and targeting gut microbiota in both current and novel treatments for T2D, highlighting potential alternative therapies including fecal microbiota transplant, prebiotics, probiotics, synbiotics, or xenobiotics. A better understanding of both the impact of the gut microbiota in the etiology of diabetes and the therapeutic potential for manipulating the gut microbiota in metabolic disease could usher in a new approach to targeted treatment options to ameliorate T2D.
科研通智能强力驱动
Strongly Powered by AbleSci AI